Teva’s Qnaze beclomethasone nasal aerosol has met all efficacy endpoints in a Phase III trial. The study involved 470 patients with perennial allergic rhinitis. After 6 weeks of treatment, patients using the product experienced significant reduction in nasal symptoms compared to those using a placebo spray. If approved, Qnaze will be the first non-aqueous intranasal corticosteroid formulation to be marketed. Read the company’s press release.
